Venus Remedies Limited has secured five marketing authorisations across Kazakhstan, Peru, Kuwait and Argentina, strengthening its international presence and expanding access to its pharmaceutical portfolio across key global markets.

The approvals cover Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate in Kuwait, and Meropenem in Argentina. The authorisations span markets across the CIS region, Latin America and the Middle East.

"These marketing authorisations mark another step in strengthening our international presence and expanding our product reach across diverse markets. We remain focused on building a strong global portfolio and making quality pharmaceutical solutions accessible to more patients worldwide," said Saransh Chaudhary, Executive Director, Venus Remedies Ltd, and CEO, Venus Medicine Research Centre (VMRC).

The company has a continued focus on expanding its portfolio for exports across geographies and building opportunities for sustainable international growth.

A leader in critical-care injectables, Venus Remedies has already established an international footprint in over 100 countries. "Our international growth strategy is centred on expanding our reach in high-potential markets while strengthening our product portfolio. We are committed to pursuing new opportunities through regulatory excellence, differentiated offerings and a sustained focus on global market expansion," said Aditi K. Chaudhary, President, International Business, Venus Remedies Ltd.